Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661323 | 1.00 | SIRT6 (0.48) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23133329 | 0.91 | MAPT (0.48) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL310356 | 0.90 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL26426465 | 0.90 | SIRT6 (0.51) | SIRT6MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29509137 | 0.88 | SIRT6 (0.60) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13832296 | 0.88 | SIRT6 (0.60) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL310188 | 0.88 | MAPT (0.43) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL310236 | 0.88 | MAPT (0.40) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL517969 | 0.88 | MAPT (0.55) | SIRT6MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30636459 | 0.88 | MAPT (0.55) | SIRT6MAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4177258-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022002241-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | 成都地奥九泓制药厂 | 2022-01-06 | — | — | WO | disclosed |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | SIRT6 2696/4885MAPT 2274/4885ALDH1A1 3986/4885 |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | ALK, EGFR, ROS1 | SIRT6 4493/4885MAPT 3028/4885ALDH1A1 2043/4885 |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | EGFR, ERBB2, ERBB3 | SIRT6 3566/4885MAPT 4673/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.